Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 13/20 | 0.45 |
| ▸ | ATM | Q13315 | 10/20 | 0.45 |
| ▸ | PRKDC | P78527 | 5/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | SERPINA2 | P20848 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14829229 | 0.92 | ATR (0.55) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL12988707 | 0.88 | ATR (0.39) | ATRATMPRKD1NR1H4PRKD3 | |
| SCHEMBL18967905 | 0.87 | ATR (0.45) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL14833083 | 0.86 | ATR (0.46) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL14829402 | 0.85 | ATR (0.38) | ATRATMPRKD1NR1H4PRKD3 | |
| SCHEMBL14829315 | 0.84 | ATR (0.38) | ATRATMPRKD1NR1H4PRKD3 | |
| SCHEMBL506085 | 0.83 | NR1H4 (0.37) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL14841400 | 0.82 | ATR (0.46) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL16105067 | 0.82 | ATR (0.36) | ATRATMPRKD1NR1H4 | |
| SCHEMBL12988946 | 0.81 | ATR (0.38) | ATRATMPRKDCGSK3BJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862709-B2 | Processes for making compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-09 | — | — | US | disclosed |
| US-20150274710-A1 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274710-A1 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, ATRIP, CHEK1 | ATR 1/4885ATM 22/4885PRKDC 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.